ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1390

A 5% Increase in Interstitial Lung Disease at 1-Year Follow-up Is Associated with Long-Term ILD Progression in Systemic Sclerosis

Alicia Hinze1, Shreyasee Amin1, Ashima Makol1, Robert Vassallo1, Cynthia Crowson2 and Brian Bartholmai1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Eyota, MN

Meeting: ACR Convergence 2021

Keywords: Computed tomography (CT), interstitial lung disease, prognostic factors, Scleroderma, Systemic, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Systemic Sclerosis & Related Disorders – Clinical Poster II (1364–1390)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: The clinical course of interstitial lung disease (ILD) in systemic sclerosis (SSc) is highly variable. Some patients experience a progressive decline in lung function while others remain stable. SSc patients with ILD may be monitored for progression by high-resolution computed tomography (HRCT), pulmonary function studies (PFT), or both, to determine i) need for therapy, or ii) stability on therapy. However, the percent change in ILD over time that constitutes significant progression on HRCT remains unclear. Additionally, whether short-term change in ILD% is associated with an increased risk for long-term ILD progression (traditionally defined as a reduction in forced vital capacity (FVC) on PFT of ≥10% predicted from baseline) is unknown. Small increases in ILD% on short-term follow-up HRCT scans may not be easily recognized due to high interrater variability in grading of the severity and extent of ILD on serial HRCT. The purpose of this study is to evaluate whether rate of change in interstitial lung abnormalities measured by quantitative CT (QCT) associates with long-term ILD progression.

Methods: All patients meeting the 2013 ACR/EULAR Classification Criteria for SSc and seen between 2007 and 2019 at our institution were identified. Subjects were eligible for inclusion in this initial proof of concept study if they had a baseline HRCT ± 2 yrs of SSc diagnosis, a follow-up HRCT within 12 months ± 6 months of baseline HRCT, and had ≥5% total ILD on baseline HRCT. Additionally, subjects were required to have a baseline PFT ± 6 months of baseline HRCT, and at least one or more PFTs after the 12-month follow-up HRCT. Subjects were excluded if the eligible HRCT scans showed pulmonary edema secondary to heart failure, pleural effusions, malignancy, or infection. HRCTs were analyzed using CALIPER (Computed Aided Lung Informatics for Pathology Evaluation and Rating) QCT software, and all parenchymal (e.g. ground glass opacities (GGO), reticular densities (RD), honeycombing (HC)) and vascular features (pulmonary vascular related structures: PVRS) were quantified and normalized by total lung volume. Total ILD% is the summation of GGO%, RD%, and HC%. ILD progression was defined as a decline in FVC of ≥10% predicted from baseline PFT. The association between rate of change in quantitative parenchymal and vascular features and ILD progression was determined using Cox models.

Results: 36 subjects (75% female; mean age 60 yrs [SD 8.4]) were analyzed. Most had limited cutaneous SSc (75%) and had no current or prior history of smoking (69%). Median time under observation was 3.3 yrs (IQR 1.4, 4.6). A total of 8/34 subjects (24%) met ILD progression endpoint. A 5% increase in total ILD conferred a 2.5-fold increase in risk of ILD progression (HR: 2.53, 95% CI 1.02-6.23) (Table 1). A 1% increase in PVRS was associated with a 5-fold increase in risk of ILD progression (HR: 5.49, 95% CI 1.11-27.24).

Conclusion: QCT detects changes in parenchymal and vascular features on 1-year follow-up HRCT that may otherwise be too small to consistently detect and characterize by visual assessment, yet are early radiomic biomarkers of long-term disease progression risk. The utility of QCT in the evaluation and follow-up of SSc-ILD warrants further study.


Disclosures: A. Hinze, None; S. Amin, None; A. Makol, None; R. Vassallo, Pfizer, 5, Bristol Myers Sqibb, 5, Sun Pharma, 5, Genentech, 5; C. Crowson, None; B. Bartholmai, AstraZenica, 1, Imbio, LLC, 9, 10, Promedior, 2.

To cite this abstract in AMA style:

Hinze A, Amin S, Makol A, Vassallo R, Crowson C, Bartholmai B. A 5% Increase in Interstitial Lung Disease at 1-Year Follow-up Is Associated with Long-Term ILD Progression in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/a-5-increase-in-interstitial-lung-disease-at-1-year-follow-up-is-associated-with-long-term-ild-progression-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-5-increase-in-interstitial-lung-disease-at-1-year-follow-up-is-associated-with-long-term-ild-progression-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology